Glycosaminoglycans in cancer therapy

Am J Physiol Cell Physiol. 2022 Jun 1;322(6):C1187-C1200. doi: 10.1152/ajpcell.00063.2022. Epub 2022 Apr 6.

Abstract

Glycosaminoglycans (GAGs) are an important component of the tumor microenvironment (TME). GAGs can interact with a variety of binding partners and thereby influence cancer progression on multiple levels. GAGs can modulate growth factors and chemokine signaling, invasion, and metastasis formation. Moreover, GAGs are able to change the physical property of the extracellular matrix (ECM). Abnormalities in GAG abundance and structure (e.g., sulfation patterns and molecular weight) are found across various cancer types and show biomarker potential. Targeting GAGs, as well as the usage of GAGs and their mimetics, are promising approaches to interfere with cancer progression. In addition, GAGs can be used as drug and cytokine carriers to induce an antitumor response. In this review, we summarize the role of GAGs in cancer and the potential use of GAGs and GAG derivatives to target cancer.

Keywords: cancer therapy; heparin; hyaluronidase; nanoparticles; proteoglycans.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Extracellular Matrix / metabolism
  • Glycosaminoglycans* / chemistry
  • Glycosaminoglycans* / metabolism
  • Glycosaminoglycans* / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Tumor Microenvironment

Substances

  • Glycosaminoglycans